Mr. Marc N. Ross
Quality Manager/Co-Owner
AQ USA Inc., d.b.a Ross Healthcare Inc.
210 S Duffner Dr., Suite A
Lynden , WA 98264
United StatesFEI 3015167023Issued Feb 12, 2026Center for Drug Evaluation and Research (CDER)
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3015167023.
Violations6
Issue DateFeb 12, 2026
Product TypeDrugs
StatusOpen
Letter Details
Firm
AQ USA Inc., d.b.a Ross Healthcare Inc.
Location
Mr. Marc N. Ross
Quality Manager/Co-Owner
AQ USA Inc., d.b.a Ross Healthcare Inc.
210 S Duffner Dr., Suite A
Lynden , WA 98264
United States
FEI Number
3015167023
Country
United States
Issue Date
February 12, 2026
Issuing Office
Center for Drug Evaluation and Research (CDER)
Product Type
Drugs
Status
Open
Summary
AQ USA Inc., d.b.a Ross Healthcare Inc. was cited for significant Current Good Manufacturing Practice (CGMP) violations in the manufacturing of drug products at its Lynden, Washington facility, which produces the same product line previously made at a Canadian facility already on Import Alert due to substantial CGMP violations. The company failed to conduct appropriate laboratory testing for each batch to ensure freedom from objectionable microorganisms and failed to establish adequate laboratory controls with scientifically sound specifications, standards, sampling plans, and test procedures for components, containers, closures, and finished drug products. These manufacturing deficiencies rendered the firm's drug products adulterated under the Federal Food, Drug, and Cosmetic Act.
AQ USA Inc., d.b.a Ross Healthcare Inc. FDA Warning Letter, February 12, 2026